The CAR T-cell Therapy Market is projected to reach $51.6 billion by 2030, at a CAGR of 43.3% from 2023 to 2030. CAR T-cell therapy is a treatment modality where T cells are engineered. The engineered CAR T cell gets activated when it encounters an antigen on a cancer cell. Activated CAR T cells multiply, and cytokines and activated T-cells cause significant inflammation focused on the cancer cell resulting in cell death. Hence, this is a widely known therapy for cancer patients.
The growth of this market is driven by increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy, and increasing R&D activities and clinical trials. However, the complex manufacturing process and adverse effects of the therapy may restrain the growth of this market. Additionally, a high scope in emerging economies, innovation in CAR T-cell therapies and manufacturing processes are creating opportunities for market growth. Moreover, the high treatment cost of therapy and the lack of skilled professionals are challenging factors for the market.
According to the World Health Organization (WHO), cancer is a leading cause of death worldwide, with 10 million deaths globally in 2020. Nearly 70% of cancer deaths occur in low & middle-income countries. According to GLOBACAN, the global number of new cancer cases will reach 24,044,406 in 2030 from 19,292,789 in 2020. When compared among the regions, in North America, the new cancer cases will reach 3,070,906 in 2030 from 2,556,862 in 2020, while in Europe, the new cancer cases will reach 4,919,893 in 2030 from 4,395,052 in 2020. In Asia, the number of new cancer cases will reach 11,889,569 in 2030 from 9,386,454 in 2020.
Cancer incidence is increasing globally due to unhealthy diets, tobacco use, alcohol consumption, sedentary lifestyles, exposure to carcinogens, obesity, and pollution. This increasing cancer incidence is also estimated to put a tremendous economic strain on various economies. Early detection and treatment are critical to reducing mortality and improving the chances of survival. Various forms of cancer treatment are available, such as surgery, chemotherapy, and radiotherapy; however, therapeutic advancements to boost the efficacy of cancer treatment have led to the development of CAR T-cell therapy. CAR T-cell therapy is a precision medicine in which the engineered CAR T-cells bind to an antigen on the cancer cells and kill them. Due to its efficacy, the therapy is fast becoming a standard cancer treatment. Hence, the increasing cancer incidence drives the demand for CAR T-cell therapy.
Click here to: Get a Free Sample Copy of this report
In 2023, the Yescarta (axicabtagene ciloleucel) Segment is Expected to Dominate the CAR T-cell Therapy Market
Based on drug type, in 2023, the Yescarta (axicabtagene ciloleucel) segment is expected to account for the largest share of the CAR T-Cell Therapy market. Yescarta (axicabtagene ciloleucel) treatment has been proven effective over other treatments. The drug has high efficacy in treating cancer in people with high-grade B-cell lymphoma (HGBL), diffuse large B-cell lymphoma (DLBCL), and primary mediastinal large B-cell lymphoma (PMBCL) that was not responding to earlier therapies. Hence, dominated the CAR T-cell therapy market.
In 2023, the CD Target Antigen Segment is Expected to Dominate the CAR T-cell Therapy Market
Based on target antigen, in 2023, the CD target antigen segment is expected to account for the largest share of the CAR T-cell therapy market. CD is expressed throughout the B-cell developmental phase to terminal differentiation into plasma cells. As this antigen is very helpful for determining malignancies, most therapies, clinical trials, and research studies are based on CD target antigens.
In 2023, the Lymphoma Segment is Expected to Dominate the CAR T-cell Therapy Market
Based on indication, in 2023, the lymphoma segment is expected to account for the largest share of the CAR T-Cell Therapy market. Lymphoma is a group of blood cancers that develop from abnormal white blood cells or lymphocytes. Due to the increased cases of lymphoma, there was a rise in the adoption of CAR T-cell therapy for treating lymphoma, contributing to the large share of this segment.
Asia-Pacific: Fastest-growing Regional Market
Based on geography, Asia-Pacific is slated to record the highest growth rate during the forecast period. The growth of this market is mainly driven by the large pool of patient population seeking cancer treatment, increasing prevalence of cancer, investments by the major players in the market, increasing government spending on healthcare, and growing disposable income of the population leading to improved access to cancer treatment.
Key Players
The key players profiled in the CAR T-cell therapy market report are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).
Scope of the Report:
CAR T-cell Therapy Market Size & Trend Analysis, by Drug Type
CAR T-cell Therapy Market Size & Trend Analysis, by Target Antigen
CAR T-cell Therapy Market Size & Trend Analysis, by Indication
CAR T-cell Therapy Market Size & Trend Analysis, by Geography
Key questions answered in the report:
The CAR T-cell therapy market study covers the market sizes & forecasts for CAR T-cell therapy used for the treatment. The report includes the value analysis of various segments and subsegments of the CAR T-cell therapy market at the regional and country levels.
The CAR T-cell therapy market is projected to reach $51.6 billion by 2030, at a CAGR of 43.3% during the forecast period.
Based on target antigen, in 2023, the CD target antigen segment is expected to account for the largest share of the CAR T-cell therapy market. Also, this segment is projected to register the highest CAGR during the forecast period due to the current and pipeline products focusing on the CD target antigen.
The lymphoma segment is slated to register the highest CAGR during the forecast period. The increasing number of lymphoma cases and the wide adoption of CAR T-cell therapy for its treatment drives the growth of this segment.
The growth of this market is driven by increasing cancer prevalence, a rise in awareness regarding CAR T-cell therapy medicine, and increasing R&D activities and clinical trials. Additionally, emerging economies, innovation in cell therapies and manufacturing innovations are creating opportunities for market growth.
The key players operating in the CAR T-cell therapy market are Novartis AG (Switzerland), bluebird bio, Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Caribou Biosciences, Inc. (U.S.), Cartesian Therapeutics, Inc. (U.S.), Pfizer Inc. (U.S.), Cellectis S.A. (France), Celyad Oncology SA (Belgium), Gilead Sciences, Inc. (U.S.), Intellia Therapeutics, Inc. (U.S.), Merck & Co., Inc. (U.S.), Amgen Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), and OncoTherapy Science, Inc. (Japan).
Emerging economies from Asia-Pacific, such as China and India, are projected to offer significant growth opportunities for entities operating in this market due to the growing clinical research infrastructure and clinical trials. This is expected to increase the demand for CAR T-cell therapy.
This report provides pre & post COVID-19 market estimates.
1. Overview
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitation
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders of the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Factors Affecting Market Growth
4.1. Overview
4.2. Drivers
4.2.1. Increasing Cancer Prevalence
4.2.2. Rise in Awareness Regarding CAR T-cell Therapy
4.2.3. Increasing R&D Activities and Clinical Trials
4.3. Restraints
4.3.1. Complex Manufacturing Process
4.3.2. Adverse Effects of the Therapy
4.4. Opportunities
4.4.1. Scope in Emerging Economies
4.4.2. Innovation in Cell Therapies and Manufacturing Processes
4.5. Challenges
4.5.1. High Cost of Therapy
4.5.2. Lack of Skilled Professionals
4.6. Regulatory Analysis
4.7. Pricing Analysis
4.8. Pipeline Product Analysis
4.9. Patient Journey
4.10. Reimbursement Policies
4.11. Porters Five Forces Analysis
5. Global CAR T-cell Therapy Market & Trend Analysis—by Brand
5.1. Overview
5.2. Abecma (idecabtagene vicleucel)
5.3. Breyanzi (lisocabtagene maraleucel)
5.4. Kymriah (tisagenlecleucel)
5.5. Tecartus (brexucabtagene autoleucel)
5.6. Yescarta (axicabtagene ciloleucel)
5.7. Carvykti (ciltacabtagene autoleucel)
5.8. Other Brands
6. Global CAR T-cell Therapy Market & Trend Analysis—by Target Antigen
6.1. Overview
6.2. CD
6.3. BCMA
6.4. HER2
6.5. Other Target Antigens
7. Global CAR T-cell Therapy Market & Trend Analysis—by Indication
7.1. Overview
7.2. Lymphoma
7.3. Acute Lymphoblastic Leukemia
7.4. Multiple Myeloma
7.5. Acute Myeloid Leukemia
7.6. Other Indications
8. CAR T-cell Therapy Market & Trend Analysis—by Geography
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.3. Europe
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Rest of Asia-Pacific
8.5. Latin America
8.6. Middle East & Africa
9. Competitive Analysis
9.1. Overview
9.2. Key Growth Strategies
9.3. Vendor Market Positioning
9.4. Competitive Dashboard
9.4.1. Industry Leaders
9.4.2. Market Differentiators
9.4.3. Vanguards
9.4.4. Emerging Companies
9.5. Market Share Analysis/Market Ranking (2022)
10. Company Profiles (Business Overview, Financial Snapshot, Product Portfolio, Strategic Developments, and SWOT Analysis)
10.1. Novartis AG
10.2. bluebird bio, Inc.
10.3. Bristol-Myers Squibb Company
10.4. Caribou Biosciences, Inc.
10.5. Cartesian Therapeutics, Inc.
10.6. Pfizer Inc.
10.7. Cellectis S.A.
10.8. Celyad Oncology SA
10.9. Gilead Sciences, Inc.
10.10. Intellia Therapeutics, Inc.
10.11. Merck & Co., Inc.
10.12 Amgen Inc.
10.13. Inovio Pharmaceuticals, Inc.
10.14. OncoTherapy Science, Inc.
10.15. Other Companies
11. Appendix
11.1. Questionnaire
11.2. Available Customization
List of Tables
Table 1 Global CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 2 Global CAR T-cell Therapy Market for Abecma (idecabtagene vicleucel), by Country/Region, 2021–2030 (USD Million)
Table 3 Global CAR T-cell Therapy Market for Breyanzi (lisocabtagene maraleucel), by Country/Region, 2021–2030 (USD Million)
Table 4 Global CAR T-cell Therapy Market for Kymriah (tisagenlecleucel), by Country/Region, 2021–2030 (USD Million)
Table 5 Global CAR T-cell Therapy Market for Tecartus (brexucabtagene autoleucel), by Country/Region, 2021–2030 (USD Million)
Table 6 Global CAR T-cell Therapy Market for Yescarta (axicabtagene ciloleucel), by Country/Region, 2021–2030 (USD Million)
Table 7 Global CAR T-cell Therapy Market for Carvykti (ciltacabtagene autoleucel), by Country/Region, 2021–2030 (USD Million)
Table 8 Global CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 9 Global CD Antigen Market, by Country/Region, 2021–2030 (USD Million)
Table 10 Global BCMA Antigen Market, by Country/Region, 2021–2030 (USD Million)
Table 11 Global HER2 Antigen Market, by Country/Region, 2021–2030 (USD Million)
Table 12 Global Other Target Antigens Market, by Country/Region, 2021–2030 (USD Million)
Table 13 Global CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 14 Global CAR T-cell Therapy Market for Lymphoma, by Country/Region, 2021–2030 (USD Million)
Table 15 Global CAR T-cell Therapy Market for Acute Lymphoblastic Leukemia, by Country/Region, 2021–2030 (USD Million)
Table 16 Global CAR T-cell Therapy Market for Multiple Myeloma, by Country/Region, 2021–2030 (USD Million)
Table 17 Global CAR T-cell Therapy Market for Acute Myeloid Leukemia, by Country/Region, 2021–2030 (USD Million)
Table 18 Global CAR T-cell Therapy Market for Other Indications, by Country/Region, 2021–2030 (USD Million)
Table 19 North America: CAR T-cell Therapy Market, by Country, 2021–2030 (USD Million)
Table 20 North America: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 21 North America: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 22 North America: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 23 U.S.: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 24 U.S.: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 25 U.S.: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 26 Canada: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 27 Canada: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 28 Canada: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 29 Europe: CAR T-cell Therapy Market, by Country/Region, 2021–2030 (USD Million)
Table 30 Europe: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 31 Europe: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 32 Europe: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 33 Germany: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 34 Germany: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 35 Germany: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 36 France: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 37 France: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 38 France: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 39 U.K.: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 40 U.K.: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 41 U.K.: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 42 Italy: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 43 Italy: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 44 Italy: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 45 Spain: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 46 Spain: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 47 Spain: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 48 Rest of Europe: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 49 Rest of Europe: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 50 Rest of Europe: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 51 Asia-Pacific: CAR T-cell Therapy Market, by Country/Region, 2021–2030 (USD Million)
Table 52 Asia-Pacific: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 53 Asia-Pacific: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 54 Asia-Pacific: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 55 China: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 56 China: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 57 China: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 58 Japan: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 59 Japan: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 60 Japan: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 61 India: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 62 India: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 63 India: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 64 Rest of Asia-Pacific: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 65 Rest of Asia-Pacific: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 66 Rest of Asia-Pacific: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 67 Latin America: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 68 Latin America: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 69 Latin America: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 70 Middle East & Africa: CAR T-cell Therapy Market, by Brand, 2021–2030 (USD Million)
Table 71 Middle East & Africa: CAR T-cell Therapy Market, by Target Antigen, 2021–2030 (USD Million)
Table 72 Middle East & Africa: CAR T-cell Therapy Market, by Indication, 2021–2030 (USD Million)
Table 73 Recent Developments, by Company, 2020—2023
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Global CAR T-cell Therapy Market, by Brand, 2023 VS. 2030 (USD Million)
Figure 8 Global CAR T-cell Therapy Market, by Target Antigen, 2023 VS. 2030 (USD Million)
Figure 9 Global CAR T-cell Therapy Market, by Indication, 2023 VS. 2030 (USD Million)
Figure 10 CAR T-cell Therapy Market, by Region
Figure 11 Impact Analysis: CAR T-cell Therapy Market
Figure 12 Market Dynamics: CAR T-cell Therapy Market
Figure 13 Global CAR T-cell Therapy Market, by Brand, 2023 VS. 2030 (USD Million)
Figure 14 Global CAR T-cell Therapy Market, by Target Antigen, 2023–2030 (USD Million)
Figure 15 Global CAR T-cell Therapy Market, by Indication, 2023–2030 (USD Million)
Figure 16 Global CAR T-cell Therapy Market, by Geography, 2023–2030 (USD Million)
Figure 17 North America: CAR T-cell Therapy Market Snapshot
Figure 18 Europe: CAR T-cell Therapy Market Snapshot
Figure 19 Asia-Pacific: CAR T-cell Therapy Market Snapshot
Figure 20 Key Growth Strategies Adopted by Leading Players, 2020—2023
Figure 21 Competitive Dashboard: Chromatography Data Systems Market
Figure 22 CAR T-cell Therapy Market: Competitive Benchmarking, by Target Antigen
Figure 23 Novartis AG: Financial Overview (2022)
Figure 24 bluebird bio, Inc.: Financial Overview (2021)
Figure 25 Bristol-Myers Squibb Company: Financial Overview (2021)
Figure 26 Cellectis S.A.: Financial Overview (2021)
Figure 27 Caribou Biosciences, Inc.: Financial Overview (2021)
Figure 28 Pfizer Inc.: Financial Overview (2021)
Figure 29 Celyad Oncology SA: Financial Overview (2022)
Figure 30 Gilead Sciences, Inc.: Financial Overview (2022)
Figure 31 Intellia Therapeutics, Inc.: Financial Overview (2021)
Figure 32 Merck & Co., Inc.: Financial Overview (2022)
Figure 33 Amgen Inc.: Financial Overview (2022)
Figure 34 Inovio Pharmaceuticals, Inc.: Financial Overview (2022)
Figure 35 OncoTherapy Science, Inc.: Financial Overview (2022)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: Dec-2022
Published Date: Jul-2022
Published Date: Jul-2022
Published Date: Nov-2021
Published Date: Aug-2021
